Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation
Nicotine replacement therapy (NRT) is widely used to limit the withdrawal symptoms associated with cigarette smoking cessation. However, the available NRT formulations are limited by their short release profiles, requiring frequent administrations along with local side effects. Thus, the objective of this study is to develop an NRT formulation that offers prolonged, sustained nicotine release. Thermoresponsive in situ gelling systems containing nicotine were prepared using poloxamer 407 (P407) and poloxamer 188 (P188). The system was optimized using a three-factor, two-level full factorial design (23). A formulation composed of P407 (20% w/w), P188 (5% w/w), and loaded with nicotine (0.5% w/w) exhibited sol-to-gel transition at a suitable temperature close to physiological temperature (30 °C). The rheological analysis demonstrated a Newtonian-like flow at room temperature, suggesting ease of administration via injection, and semisolid gel status at physiological temperature. The optimized formulation successfully sustained nicotine in vitro release over 5 days following single administration. The findings suggest that poloxamer based in situ gelling systems are promising platforms to sustain the release of nicotine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Gels (Basel, Switzerland) - 8(2022), 2 vom: 12. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hulambukie, Eileen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Design expert |
|---|
| Anmerkungen: |
Date Revised 01.03.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/gels8020114 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337321132 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337321132 | ||
| 003 | DE-627 | ||
| 005 | 20231225234141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/gels8020114 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337321132 | ||
| 035 | |a (NLM)35200495 | ||
| 035 | |a (PII)114 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hulambukie, Eileen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Nicotine replacement therapy (NRT) is widely used to limit the withdrawal symptoms associated with cigarette smoking cessation. However, the available NRT formulations are limited by their short release profiles, requiring frequent administrations along with local side effects. Thus, the objective of this study is to develop an NRT formulation that offers prolonged, sustained nicotine release. Thermoresponsive in situ gelling systems containing nicotine were prepared using poloxamer 407 (P407) and poloxamer 188 (P188). The system was optimized using a three-factor, two-level full factorial design (23). A formulation composed of P407 (20% w/w), P188 (5% w/w), and loaded with nicotine (0.5% w/w) exhibited sol-to-gel transition at a suitable temperature close to physiological temperature (30 °C). The rheological analysis demonstrated a Newtonian-like flow at room temperature, suggesting ease of administration via injection, and semisolid gel status at physiological temperature. The optimized formulation successfully sustained nicotine in vitro release over 5 days following single administration. The findings suggest that poloxamer based in situ gelling systems are promising platforms to sustain the release of nicotine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a design expert | |
| 650 | 4 | |a factorial design | |
| 650 | 4 | |a gelation temperature | |
| 650 | 4 | |a nicotine | |
| 650 | 4 | |a poloxamers | |
| 650 | 4 | |a prolonged release | |
| 650 | 4 | |a rheological properties | |
| 650 | 4 | |a sustained release | |
| 700 | 1 | |a Abdeltawab, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Duarah, Sanjukta |e verfasserin |4 aut | |
| 700 | 1 | |a Svirskis, Darren |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Manisha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gels (Basel, Switzerland) |d 2014 |g 8(2022), 2 vom: 12. Feb. |w (DE-627)NLM273273515 |x 2310-2861 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2022 |g number:2 |g day:12 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/gels8020114 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2022 |e 2 |b 12 |c 02 | ||